The authors proposed that due to the TYR inhibitory activity of 35, as well as its ability to decrease melanin production in melanoma cells in a dose-dependent manner, this small molecule possesses the potential to be explored as a therapeutic agent. This evidence concerns the gene TYR and melanoma.